Composition for prevention and treatment on viral infectious myocarditis

[0012] The above description is only an overview of the technical solutions of the present invention. In order to have a clearer understanding of the technical means of the present invention, which can be implemented in accordance with the contents of the description and conventional technical means in the field, the following describes the animal test examples of the present invention in further detail .

[0013] The preparation method of the compound Trefolane A involved in the present invention can be found in the literature (Trefolanes A-D with aDiterpene-Sesquiterpene Skeleton from Supercritical Fluid Extracts of Helianthus annuus L. var. Arianna Org. Lett., 2015, 17(19), 4730-4733).

[0014] Fritillaria saponin A, CAS: 102040-03-9, is available in the market.

[0015] Modeling: 4-week-old clean mice, weighing 7-11g, male, the environment temperature of the animal room is 27℃~30℃, and the humidity is 35%~45%. 616 mice were randomly divided into 22 groups, each with 28 mice, divided into 20 groups of administration group, a normal group, and a control group. 4-week-old mice (9±2)g were intraperitoneally inoculated with 0.1mL CVB3 virus solution to establish a viral myocarditis (VMC) model. The normal control group was injected intraperitoneally with 0.1mL virus-free culture solution. The administration was started 72 hours after the virus inoculation, by intraperitoneal injection. Intraperitoneal injection. The administration group was given 100mg of drug per kilogram of body weight, and the drug was temporarily dispensed before the experiment, and injected intraperitoneally with a volume of 0.1 mL; the normal group and the control group were injected with 0.1 mL of normal saline intraperitoneally. It is injected once a day and fed with ordinary pellets. Dosing is continued for 3 weeks.

[0016] experimental method

[0017] Serum biochemical indicators include malondialdehyde (MDA) and nitric oxide (NO) biochemical indicator determination: the reagents were purchased from Nanjing Jiancheng Bioengineering Company, and the detection was performed according to the product manual. The detection units were nmol mL-1 and μmol L respectively. -1.

[0018] Comparison of mortality of mice in each group of virus inoculation; record the number of deaths of mice in each group during the experiment. Chi-square test was used for comparison between groups.

[0019] A is Trefolane A, and B is saponin A.

[0020] Mortality of mice in each group, comparison of malondialdehyde (MDA) and nitric oxide (NO) content (x±s)

[0021]

[0022]

[0023] Results The mortality of mice in each group was compared with the content of malondialdehyde (MDA nmol·mL-1) and nitric oxide (NOμmol·L-1). After the experiment, the administration of Trefolane A and saponin A was 15: The mortality of mice in the 1-17:1 group, malondialdehyde (MDA nmol·mL-1) and nitric oxide (NOμmol·L-1) levels were significantly lower than those of other administration groups and the control group. The general condition, survival rate, serum malondialdehyde (M DA) and serum nitric oxide (NO) of mice with coxsackie virus infectious myocarditis at a ratio of 18:1-15:1 between Trefolane A and A. ) And other biochemical indicators have a good improvement effect, and the effect of other proportion groups is not significant.